Kailera Therapeutics Files Form 4
Ticker: KLRA · Form: 4 · Filed: Apr 22, 2026 · CIK: 0002096997
Sentiment: neutral
Topics: insider-filing, ownership-change
TL;DR
Kailera Therapeutics filed a Form 4 on 4/22/26 for ownership changes as of 4/20/26.
AI Summary
On April 20, 2026, Kailera Therapeutics, Inc. filed a Form 4, indicating a change in beneficial ownership of securities. The filing was accepted on April 22, 2026. The company's mailing and business addresses are located in Lianyungang, Jiangsu Province, China.
Why It Matters
Form 4 filings report changes in ownership by insiders, which can signal their confidence or lack thereof in the company's future prospects.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of ownership changes and does not inherently indicate significant risk.
Key Players & Entities
- Kailera Therapeutics, Inc. (company) — Issuer
- 0002096997 (company) — Issuer CIK
- Jiangsu Hengrui Pharmaceuticals Co., Ltd. (company) — Reporting Company
- 0002080343 (company) — Reporting Company CIK
- 2026-04-20 (date) — Period of Report
- 2026-04-22 (date) — Filing Date
FAQ
What is the specific nature of the change in beneficial ownership reported in this Form 4?
The provided text does not specify the nature of the change in beneficial ownership, only that a Form 4 was filed.
Who is the reporting entity and who is the issuer in this filing?
Jiangsu Hengrui Pharmaceuticals Co., Ltd. is the reporting entity, and Kailera Therapeutics, Inc. is the issuer.
When was the period of report for this ownership change?
The period of report was April 20, 2026.
What are the business and mailing addresses for Kailera Therapeutics, Inc. as listed in the filing?
The business and mailing addresses for Kailera Therapeutics, Inc. are both listed as NO. 7 KUNLUNSHAN ROAD ECON. AND TECHNOLOGICAL DEVELOPMENT ZONE LIANYUNGANG JIANGSU PROVINCE China 00000.
What is the CIK number for Kailera Therapeutics, Inc.?
The CIK number for Kailera Therapeutics, Inc. is 0002096997.
Filing Details
This Statement of Changes in Beneficial Ownership (Form 4) was filed with the SEC on April 22, 2026 regarding Kailera Therapeutics, Inc. (KLRA). Form 4 filings disclose purchases, sales, or other changes in ownership by company insiders such as officers, directors, and major shareholders.